- Home
- RSF vs JNJ Comparison
RSF vs JNJ Comparison
Compare RSF & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSF | JNJ |
|---|---|---|
| Founded | 2016 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 542.4B |
| IPO Year | 2015 | 2003 |
Fundamental Metrics
Financial Performance| Metric | RSF | JNJ |
|---|---|---|
| Price | $14.23 | $266.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 20 |
| Target Price | N/A | ★ $238.20 |
| AVG Volume (30 Days) | 5.7K | ★ 5.6M |
| Earning Date | 01-01-0001 | 04-14-2026 |
| Dividend Yield | ★ 10.61% | 2.36% |
| EPS Growth | N/A | ★ 90.50 |
| EPS | N/A | ★ 4.41 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $6.63 |
| Revenue Next Year | N/A | $7.43 |
| P/E Ratio | ★ N/A | $60.37 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.23 | $173.33 |
| 52 Week High | $15.07 | $281.07 |
Technical Indicators
Market Signals| Indicator | RSF | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 26.87 | 53.99 |
| Support Level | N/A | $263.83 |
| Resistance Level | $14.67 | $275.69 |
| Average True Range (ATR) | 0.05 | 4.32 |
| MACD | -0.01 | -0.94 |
| Stochastic Oscillator | 0.00 | 35.82 |
Price Performance
Historical ComparisonAbout RSF RiverNorth Capital and Income Fund
RiverNorth Capital and Income Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income by investing in credit instruments, including a portfolio of securities of specialty finance and other financial companies.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.